TRADING QUOTES                                2:14 PM   August 16, 2018

IPO Terms/Details

Total Public Proceeds at IPO ($mm):$310.0
% Held in Trust:100.0%
$ Held in Trust per Unit:$10.00
Mgmt's Sector Expertise/Focus:North American or European healthcare-related businesses
IPO Date:Oct. 11, 2016
Months to Complete:24
Deadline Date:Oct. 11, 2018
Unit Structure (AHPAU)
Share (AHPA):1 Class A Ordinary Share
Warrant (AHPAW):1 Warrant
Public Warrant Terms:
Exercise Price:$11.50
Redemption Price:$18.00
Cash or Cashless Redemption:Mgmt's Discretion
Underwriters:
Book-runner(s) and Lead Mgr(s):Credit Suisse
Co-Manager(s):I-Bankers Securities, Inc.
Fees (Upfront/Deferred):2.0% / 3.5%
Lawyers:
Issuer's Counsel:Weil, Gotshal & Manges, LLP
Underwriter's Counsel:Skadden, Arps, Slate, Meagher & Flom LLP
  

MANAGEMENT & BOARD


Executive Officers

David Burgstahler, 48
President, CEO and Director

Mr. Burgstahler is a co-managing partner and president of Avista and has served in various capacities at Avista since its founding in 2005. Prior to forming Avista, he was a Partner of DLJMB from 2004 to 2005 and he served in various capacities at DLJMB and its affiliates from 1995 to 2005. Prior to DLJMB, Mr. Burgstahler worked at Andersen Consulting (now known as Accenture) and McDonnell Douglas (now known as Boeing). He currently serves as a Director of ACP Mountain Holdings, Inc., AngioDynamics Inc. (NASDAQ: ANGO), ConvaTec Healthcare BS.a.r.l, INC Research Holdings, Inc. (NASDAQ: INCR), Lantheus Holdings, Inc. (NASDAQ: LNTH), Osmotica Holdings, S.C.Sp, and WideOpenWest, LLC. Mr. Burgstahler also previously served on the Boards of Directors of Armored AutoGroup, BioReliance Corp., Focus Diagnostics, Inc., Strategic Partners, LLC, Visant Corp. and Warner Chilcott PLC (NASDAQ: WCRX). Mr. Burgstahler is also a Trustee of the Trinity School in New York City. Mr. Burgstahler received a B.S. from the University of Kansas and an M.B.A. from Harvard Business School.


John Cafasso, 43
CFO

Prior to joining Avista, Mr. Cafasso was in the asset management division of Credit Suisse from 2001 to May 2011, where he was responsible for the accounting and reporting for Credit Suisse’s direct private equity funds. Prior to joining Credit Suisse, Mr. Cafasso was a Manager at KPMG, LLP in the financial services practice. Mr. Cafasso is a Certified Public Accountant and received a B.B.A. degree from Hofstra University.


Benjamin Silbert, 45
General Counsel and Secretary

Prior to joining Avista, Mr. Silbert was at DLJMB from 2001 to 2005. He advised DLJMB as internal counsel on a number of investments and divestitures, in addition to fund and partnership matters. Prior to joining DLJMB, Mr. Silbert was a lawyer in the private equity and mergers and acquisitions practice groups of Morgan, Lewis & Bockius LLP, which he joined in 1996. Mr. Silbert currently serves on the Board of Directors of WideOpenWest, LLC. Mr. Silbert received a B.A. from Haverford College and a J.D. from Columbia Law School.


Board of Directors

Thompson Dean, 58
Executive Chairman of the Board of Directors

Mr. Dean is a co-managing partner and chief executive officer of Avista and has served in various capacities at Avista since its founding in in 2005. From 1995 to 2005, Mr. Dean served as Co-Managing Partner of DLJMB and was Chairman of the investment committees of DLJMB I, DLJMB II, DLJMB III and DLJ Growth Capital Partners. Mr. Dean currently serves on the boards of Acino Pharma AG, ConvaTec Healthcare BS.a.r.l., Sidewinder Drilling, Inc. and Zest Anchors LLC. Mr. Dean is a former trustee of Choate Rosemary Hall and The Eaglebrook School. In addition, he serves on various committees of the Boys Club of New York, the Lenox Hill Neighborhood Association and the Museum of the City of New York. Mr. Dean received a B.A. from the University of Virginia, where he was an Echols Scholar, and an M.B.A. with high distinction from Harvard Business School, where he was a Baker Scholar.


Håkan Björklund, 60
Director

Dr. Björklund has been a healthcare industry advisor to Avista since October 2011. Dr. Björklund worked closely with Avista on the development of Nycomed A/S prior to its sale to Takeda Pharmaceutical Company Limited. Under Dr. Björklund’s leadership from 1999 to 2011, Nycomed A/S grew from a predominantly Scandinavian business into a global pharmaceutical company, with Dr. Björklund leading the company through numerous acquisitions. Prior to Nycomed A/S, Dr. Björklund was Regional Director at Astra AB (now AstraZeneca plc) from 1996 to 1999 and, prior to that he was President of Astra Draco AB from 1991 to 1996. Dr. Björklund is Chairman of the Board of Directors at Acino Pharma AG, Swedish Orphan Biovitrum AB (SOBI) and Trimb Healthcare AB and is a member of the Boards of Directors of Alere Inc. (NYSE: ALR), Atos Medical AB, Coloplast A/S (CPH: COLO-B) and Kibion AB. He was also a director at Danisco A/S until its recent acquisition by Dupont. Dr. Björklund received a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.


Charles Harwood, 63
Director

Mr. Harwood has served as a healthcare industry advisor to Avista since 2007. Mr. Harwood previously served as the President and Chief Executive Officer of BioReliance Corp., a pharmaceutical services company engaged in biologic product testing and specialty toxicology testing, from April 2009 until March 2013, after its sale to Sigma-Aldrich Co. LLC in January 2012. Prior to that, Mr. Harwood was President and Chief Executive Officer of Focus Diagnostics, Inc. from 2002 until the company’s sale in July 2006. From 1993 to 2001, Mr. Harwood held several positions, including Chief Financial Officer and Senior Vice President of Venture Development at Covance Inc., a drug development services company, where he led numerous acquisitions and divestitures, as well as the spin-off of Covance Inc. from Corning Inc. in January 1997. Prior to working at Covance Inc., Mr. Harwood worked in commercial real estate development and in the Medical Products Group of the Hewlett-Packard Company. He is the Chairman of the Board of Directors of ACP Mountain Holdings, Inc. and is a member of the Board of Directors of INC Research Holdings, Inc. (NASDAQ: INCR). He also previously served as a director of BioReliance Corp. from April 2007 until January 2012. Mr. Harwood received a B.A. from Stanford University and an M.B.A. from Harvard Business School.


Brian Markison, 57
Director

Mr. Markison has been a healthcare industry advisor to Avista since September 2012. Mr. Markison has more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He is currently the Chief Executive Officer of Osmotica Holdings, S.C.Sp. Prior to that he was the President and Chief Executive Officer and Member of the Board of Directors of Fougera Pharmaceuticals Inc. from July 2011 to July 2012, a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz Ltd., the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, Inc., which he joined as Chief Operating Officer in March 2004, and was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King Pharmaceuticals, Inc., Mr. Markison held various senior leadership positions at Bristol-Myers Squibb Company, including President of Oncology, Virology and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. He serves as Chairman of the Board of Lantheus Holdings, Inc. (NASDAQ: LNTH), Osmotica Holdings, S.C.Sp. and Rosetta Genomics Ltd. (NASDAQ: ROSG) and is on the Boards of Directors of Alere, Inc. (NYSE: ALR) and Immunomedics, Inc. (NASDAQ: IMMU). He is also a Director of the College of New Jersey. Mr. Markison received a B.S. degree from Iona College.


Robert O’Neil, 66
Director

Mr. O’Neil has served as a healthcare industry advisor to Avista since April 2015. Most recently, he was Worldwide Vice President of Business Development for Johnson & Johnson’s Consumer Group of Companies from November 2002 to May 2014 and concurrently served as a Member of the Consumer Group Operating Committee and a Board Member for the Johnson & Johnson Development Corp. Previously, he was Vice President, Business Development, for Johnson & Johnson’s Pharmaceutical Group from 1994 to November 2002. From 1991 to 1993, Mr. O’Neil was Senior Vice President, Sales, Marketing, New Product Development, for Ortho McNeil Pharmaceutical (a wholly-owned company of Johnson & Johnson). He was also a Member of the Ortho McNeil Pharmaceutical Management Board. Prior to that role, Mr. O’Neil held various leadership positions in sales and marketing with Johnson & Johnson beginning in 1974. Mr. O’Neil currently serves on the Board of Directors of Trimb Healthcare AB. Mr. O’Neil received a B.S. from the Stillman School of Business at Seton Hall University and a M.B.A. from the Tobin College of Business at St. John’s University.













 



Leave a Reply